While amivantamab, an EGFR-MET bispecific antibody, was approved for the treatment of EGFR Exon 20 insertion NSCLC based on the Phase I CHRYSALIS trial, patients with active or untreated brain metastases were excluded from the study, and CNS monitoring was not required limiting interpretation of CNS activity [54]. Here, EGFR is linked to non-small cell lung carcinoma.